As a Ph.D. holder in Cellular and Molecular Biology, Coralie Carron assumes the pivotal…
A European leader in the secure extraction of imaging and clinical data to accelerate medical research, Medexprim is one of the companies selected among the 5 winning consortia of the call for interest “Data, AI and health pathways” of the Strategic Committee of the health industries and technologies (CSF-ITS).
This call for interest aims to identify and support projects proposing disruptive innovations based on the use of health data in order to improve healthcare pathways, federate players and structure the AI and Health sector.
In partnership with the Institut Mutualiste Montsouris, the Institut du Thorax Curie-Montsouris, and other data partners (hospital data providers), Medexprim is carrying out the CardioToxIMT project, which aims to assess the risks of cardiac toxicity in immunotherapy care paths.
Julie Baussand, Health Innovation Projects Director at Medexprim: “A major innovation transforming the treatment and management of patients for many cancers, immunotherapies are responsible for significant adverse effects. In particular, cardiac toxicities can lead to treatment discontinuation and become the main problem for patients. By defining cardiotoxicity measures and characterizing predictive or prognostic markers based on Real-World data, the CardioToxIMT project will help optimize each patient’s pathway by taking this individual cardiological risk into account in the care pathway.”
Like the four other selected projects, CardioToxIMT will benefit from a one-year personalized support program to accelerate its deployment and benefit from the expertise of CSF-ITS members.
REAL-WORLD EVIDENCE FOR BETTER CARE
Medexprim is the European leader in secure imaging and clinical data extraction to accelerate medical research. As a Real-World data specialist, Medexprim builds bridges between European academic hospitals, and pharmaceutical, AI and medical device companies. In compliance with the GDPR, Medexprim helps hospitals boost their clinical research strategy and valorize their data, through a suite of software and services designed with and for clinicians. Medexprim provides its partners with secure access to complex, regulatory-grade, multi-omics and multicentric datasets to serve oncology, neurology and cardiology, and help solve the “one patient, one disease, one treatment” equation to accelerate personalized medicine.
Press contact: Anne-Sophie Labeta – email@example.com